Regulus Therapeutics Inc (RGLS) concluded trading on Wednesday at a closing price of $7.98, with 28.53 million shares of worth about $227.65 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 454.17% during that period and on April 30, 2025 the price saw a gain of about 136.80%. Currently the company’s common shares owned by public are about 65.50M shares, out of which, 53.18M shares are available for trading.
Stock saw a price change of 212.94% in past 5 days and over the past one month there was a price change of 356.00%. Year-to-date (YTD), RGLS shares are showing a performance of 405.06% which increased to 229.75% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.83 but also hit the highest price of $3.73 during that period. The average intraday trading volume for Regulus Therapeutics Inc shares is 1.29 million. The stock is currently trading 225.75% above its 20-day simple moving average (SMA20), while that difference is up 339.98% for SMA50 and it goes to 401.44% higher than SMA200.
Regulus Therapeutics Inc (NASDAQ: RGLS) currently have 65.50M outstanding shares and institutions hold larger chunk of about 67.96% of that.
The stock has a current market capitalization of $528.62M and its 3Y-monthly beta is at 0.89. It has posted earnings per share of -$0.88 in the same period. It has Quick Ratio of 10.52 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RGLS, volatility over the week remained 14.92% while standing at 12.74% over the month.
Analysts are in expectations that Regulus Therapeutics Inc (RGLS) stock would likely to be making an EPS of -0.26 in the current quarter, while forecast for next quarter EPS is -0.31 and it is -1.56 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.43 which is -0.2 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.29 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -50.41% while it is estimated to decrease by -25.57% in next year. EPS is likely to shrink at an annualized rate of -13.90% for next 5-years, compared to annual growth of 40.21% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on March 27, 2025 offering an Overweight rating for the stock and assigned a target price range of between $3 and $6 to it. Coverage by Oppenheimer stated Regulus Therapeutics Inc (RGLS) stock as an Outperform in their note to investors on August 02, 2024, suggesting a price target of $7 for the stock. On March 18, 2024, Leerink Partners Initiated their recommendations, while on March 28, 2018, B. Riley FBR Inc. Initiated their ratings for the stock with a price target of $1. Stock get an Outperform rating from Leerink Partners on January 05, 2018.
